Advertisement
U.S. markets close in 1 hour 22 minutes
  • S&P 500

    5,253.03
    +4.54 (+0.09%)
     
  • Dow 30

    39,776.04
    +15.96 (+0.04%)
     
  • Nasdaq

    16,379.76
    -19.76 (-0.12%)
     
  • Russell 2000

    2,123.07
    +8.72 (+0.41%)
     
  • Crude Oil

    83.15
    +1.80 (+2.21%)
     
  • Gold

    2,241.90
    +29.20 (+1.32%)
     
  • Silver

    24.98
    +0.22 (+0.90%)
     
  • EUR/USD

    1.0796
    -0.0034 (-0.31%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2622
    -0.0016 (-0.13%)
     
  • USD/JPY

    151.3860
    +0.1400 (+0.09%)
     
  • Bitcoin USD

    70,805.21
    +2,056.32 (+2.99%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Amgen 2nd quarter profit rises; announces up to 2,900 job cuts

July 29 (Reuters) - Amgen Inc on Tuesday posted higher-than-expected second-quarter profit in a rebound from a disappointing first quarter, helped by strong sales of its rheumatoid arthritis drug Enbrel, and it significantly raised its full-year earnings forecast.

The world's largest biotechnology company also said it would cut 12 to 15 percent of its workforce and close two plants in a series of restructuring moves aimed at reallocating resources as it prepares for the eventual launch of new medicines it hopes will drive future growth.

Amgen said net profit rose to $1.55 billion, or $2.01 per share, from a profit of $1.26 billion, or $1.65 per share, a year ago.

Excluding items, Amgen earned $2.37 per share. Analysts on average expected $2.07 per share, according to Thomson Reuters I/B/E/S.

Revenue rose 11 percent to $5.2 billion, exceeding Wall Street estimates of $4.89 billion.

(Reporting by Bill Berkrot; Editing by James Dalgleish)

Advertisement